VELTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELTIN (VELTIN).
Fixed-dose combination of clindamycin (a lincosamide antibiotic) and tretinoin (a retinoid). Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Tretinoin reduces microcomedone formation by normalizing follicular keratinization.
| Metabolism | Clindamycin: Hepatic metabolism primarily via CYP3A4, with some metabolites active. Tretinoin: Oxidative metabolism via CYP450 enzymes, with further conjugation and excretion. |
| Excretion | Renal (primarily unchanged drug, ~60% within 96 hours); fecal (~35%, with ~9% as metabolites). |
| Half-life | Terminal elimination half-life is approximately 17 hours (range 10-24 h) after oral administration. This supports twice-daily dosing in adults. |
| Protein binding | Clindamycin is 60-95% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd is approximately 0.6 L/kg (43 L in a 70 kg adult), indicating distribution into total body water. |
| Bioavailability | Oral: ~90% absorbed; however, systemic bioavailability is reduced by extensive first-pass metabolism (to active and inactive metabolites). |
| Onset of Action | Oral: Clinical effect (improvement in acne lesions) typically observed within 2-4 weeks of continuous therapy. |
| Duration of Action | Duration of action is approximately 24 hours, consistent with twice-daily dosing. Maximal therapeutic benefit may require 8-12 weeks of treatment. |
| Molecular Weight | Clindamycin: 424.98 Da; Tretinoin: 300.44 Da. Combined product: not applicable. |
Apply a thin layer to affected area once daily in the evening; topical, not for oral or ophthalmic use.
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for renal impairment; not studied in severe renal impairment. |
| Liver impairment | No specific dosage adjustment provided; caution in severe hepatic impairment due to potential increased systemic absorption. |
| Pediatric use | Safety and efficacy in pediatric patients below 9 years of age have not been established; for ages 9 and above, same as adult dosing. |
| Geriatric use | No specific geriatric dosage adjustments; use caution due to potential increased sensitivity and age-related skin changes. |
| 1st trimester | VELTIN (clindamycin phosphate 1.2% and tretinoin 0.025% gel) is not recommended for use during pregnancy. Tretinoin is a retinoid and may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. Tretinoin has been associated with teratogenic effects in animal studies. Clindamycin is generally considered safe for use in pregnancy, but combined with tretinoin, the risk is primarily due to the retinoid component. |
| 2nd trimester | Contraindicated in the second trimester due to potential teratogenic effects of tretinoin. Use only if clearly needed and after careful consideration of risks vs. benefits. |
| 3rd trimester | Contraindicated in the third trimester. Although systemic absorption of topical tretinoin is minimal, the risk of fetal harm cannot be excluded. Clindamycin is generally safe, but the combination product should be avoided. |
Clinical note
Comprehensive clinical and safety monograph for VELTIN (VELTIN).
| Placental transfer | Topical tretinoin has minimal systemic absorption (<5%), but it does cross the placenta to some extent. Animal studies have shown tretinoin can cross the placental barrier. Clindamycin can cross the placental barrier after oral or parenteral administration; topical use results in much lower systemic levels but transfer is possible. |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyHypersensitivity to any component of the formulationHistory of allergic reactions to clindamycin, tretinoin, or lincomycin analogsActive eczemaSunburn or damaged skin
| Precautions | Avoid contact with eyes, mouth, and mucous membranes., Photosensitivity: Minimize sun exposure and use sunscreen., Local skin reactions (erythema, peeling, dryness, pruritus) may occur., Colitis (including pseudomembranous colitis) has been reported with topical clindamycin. |
| Food/Dietary | No specific food interactions. Avoid excessive intake of vitamin A supplements or foods rich in vitamin A (e.g., liver) due to additive retinoid effects. |
Loading safety data…
| Breastfeeding | It is not known whether topical tretinoin is excreted in human milk. Clindamycin is excreted in human milk after oral administration, and it is unknown after topical application. Due to the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Caution should be exercised when VELTIN is administered to a nursing woman. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | VELTIN contains clindamycin phosphate 1.2% and tretinoin 0.025%. Tretinoin is a retinoid; topical use is associated with minimal systemic absorption. However, retinoids are known teratogens when absorbed systemically. First trimester: theoretical risk of retinoid embryopathy (CNS, cardiovascular, craniofacial defects). Second/third trimester: risk likely low but avoid unless necessity. No adequate human studies. |
| Fetal Monitoring | Monitor for signs of excessive skin irritation or retinoid toxicity. Fetal monitoring: standard prenatal care; discuss potential theoretical risks with patient. No specific fetal tests required. |
| Fertility Effects | No known effects on fertility. Topical tretinoin and clindamycin have minimal systemic absorption; no impairment of reproductive function reported. |
| Clinical Pearls |
| VELTIN is a fixed-dose combination of clindamycin 1.2% and tretinoin 0.025% gel. It is first-line for mild-to-moderate acne vulgaris, combining antibacterial and comedolytic effects. Apply pea-sized amount to entire face, avoiding eyes, mouth, and mucous membranes. Avoid concomitant use with other topical retinoids or benzoyl peroxide due to increased irritation. Use sunscreen daily due to photosensitivity from tretinoin. Improvement may take 2–6 weeks; full effect by 12 weeks. Discontinue if severe dermatitis develops. Not for use during pregnancy (tretinoin is teratogenic). |
| Patient Advice | Apply a pea-sized amount to your entire face once daily at bedtime, after washing and drying your face. · Avoid contact with eyes, lips, nostrils, and open wounds. If contact occurs, rinse thoroughly with water. · Use a moisturizer and sunscreen (SPF 30+) daily as this medication increases sun sensitivity. · You may experience temporary redness, peeling, or stinging; this usually improves with continued use. · Do not use with other acne products, especially those containing benzoyl peroxide or salicylic acid, without consulting your doctor. · Avoid waxing, chemical peels, or laser treatments while using this product. · If you are pregnant, trying to become pregnant, or breastfeeding, do not use this medication; discuss with your doctor. · Store at room temperature, away from heat and open flame (gel is flammable). · Wash hands immediately after applying. |